Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Chronic cough symbols : AGNPF save search
Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Published: 2022-02-04 (Crawled : 15:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -3.69%
H: 1.03%
C: -3.33%
phase 2 als chronic cough enroll
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study
Published: 2022-01-14 (Crawled : 15:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 9.2%
H: 0.0%
C: -4.78%
fda phase 2 als phase 2b positive chronic cough
Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial
Published: 2021-12-02 (Crawled : 16:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -0.28%
H: 0.14%
C: -5.57%
phase 2 trial chronic cough enroll
Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
Published: 2021-10-08 (Crawled : 12:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -7.45%
H: 16.61%
C: 11.3%
fda phase 2 chronic cough
Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.
Published: 2021-09-20 (Crawled : 12:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
| Email alert
Add to watchlist
phase 2 chronic cough
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.